Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products, comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue based products; and COALITION, COALITION MIS, COALITION AGX, MONUMENT, MAGNIFY-S, HEDRON IATM, HEDRON ICTM, INDEPENDENCE, INDEPENDENCE MIS, FORTIFY and XPAND families, SABLETM, RISE, RISE INTRALIF, RISE-L, ELSA, ELSA ATP, RASS, ALTERA, ARIEL, LATIS, CALIBER and CALIBER-L products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
IPO Year: 2012
Exchange: NYSE
Website: globusmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $97.00 | Underperform → Neutral | BofA Securities |
| 12/2/2024 | $83.00 → $100.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/7/2024 | $60.00 → $78.00 | Equal Weight → Overweight | Wells Fargo |
| 5/20/2024 | $60.00 → $80.00 | Neutral → Overweight | Piper Sandler |
| 3/18/2024 | $60.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | $75.00 | Buy | ROTH MKM |
| 9/19/2023 | $61.00 | Hold → Buy | Stifel |
| 3/30/2023 | $67.00 | Hold → Buy | Canaccord Genuity |
| 2/13/2023 | $83.00 → $63.00 | Buy → Underperform | BofA Securities |
| 2/10/2023 | $67.00 | Overweight → Equal Weight | Wells Fargo |
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
SD - GLOBUS MEDICAL INC (0001237831) (Filer)
144 - GLOBUS MEDICAL INC (0001237831) (Subject)
10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)
BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00
Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously
Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously
Piper Sandler upgraded Globus Medical from Neutral to Overweight and set a new price target of $80.00 from $60.00 previously
BTIG Research upgraded Globus Medical from Neutral to Buy and set a new price target of $60.00
ROTH MKM initiated coverage of Globus Medical with a rating of Buy and set a new price target of $75.00
Stifel upgraded Globus Medical from Hold to Buy and set a new price target of $61.00
Canaccord Genuity upgraded Globus Medical from Hold to Buy and set a new price target of $67.00
BofA Securities downgraded Globus Medical from Buy to Underperform and set a new price target of $63.00 from $83.00 previously
Wells Fargo downgraded Globus Medical from Overweight to Equal Weight and set a new price target of $67.00
AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share ("EPS") was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales "Our third quarter results reflect the enduring strength of our business. We've continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering
AUDUBON, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2024 after the market close on Tuesday, November 5, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w
AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net sales were $629.7 million, an increase of 115.9% or 117.3% on a constant currency basisGAAP net income for the quarter was $31.8 millionGAAP diluted earnings per share ("EPS") was $0.23 and non-GAAP diluted EPS was $0.75Non-GAAP adjusted EBITDA was $190.4 million, or 30.2% of net sales "I'm pleased with the quarterly results, demonstrating our team's strong performance as we continue to execute our long-term growth strategy, deliver on NuVasive integration plans, laun
AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 6, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast
AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net sales were $606.7 million, an increase of 119.3%, or 119.8% on a constant currency basisGAAP net loss for the quarter was $7.1 millionGAAP diluted earnings per share ("EPS") was ($0.05) and non-GAAP diluted EPS was $0.72Non-GAAP adjusted EBITDA was $166.6 million, or 27.5% of net sales "Since the NuVasive merger closed in September of last year, we worked aggressively to execute our integration strategy and are making significant progress towards rapidly reaching steady state
AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 7, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcasts.
AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a constant currency basisGAAP net income for the quarter was $15.0 millionGAAP diluted earnings per share ("EPS") was $0.11 and non-GAAP diluted EPS was $0.60Non-GAAP adjusted EBITDA was $170.0 million, or 27.6% of net sales Full Year 2023: Worldwide net sales were $1,568.5 million, an increase of 53.3% on an actual and constant currency b
AUDUBON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Tuesday, February 20, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-
AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023. The merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date. Worldwide net sales were $383.6 million, an increase of 51.0%.GAAP net income for the quarter was $1.0 millionGAAP diluted earnings per share ("EPS") was $0.01 and non-GAAP diluted EPS was $0.57Non-GAAP adjusted EBITDA was $112.9 million, or 29.4% of net salesStand-alone Globus Medical net sales were $281.2 million, an increase of 10.7%
AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2023 after the market close on Tuesday, November 7, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis. "2024 was an exceptional year of execution and achievement for Globus Medical. With the NuVasive merger, we believe we created the strongest sales fo
AUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation. Freehand navigation provides surgeons with real-time visualization of instrument placement, to reduce the reliance on X-ray imaging during spine surgery. This also facilitates accurate placement of screws and interbody spacer implants and may reduce OR radiation when compared to conventional fluoroscopy. ExcelsiusHub™ offers advantages over other n
AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share ("EPS") was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales "Our third quarter results reflect the enduring strength of our business. We've continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering
AUDUBON, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, is participating in the 40th Annual Meeting of the Orthopedic Trauma Association (OTA) in Montréal, Canada, October 23—26. Join Globus at booth #361 during OTA for product demonstrations of the PRECICE™ technologies and our full orthopedic trauma product portfolio. Special highlights include our most recent additions to the portfolio including TENSOR™ Suture Button, ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws. Globus Medical will also showcase the most recent addition to the PRECICE™ Plat
AUDUBON, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2024 after the market close on Tuesday, November 5, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w
AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio. Globus has introduced several new system extensions so far in 2024 and received 510(k) clearance from the U.S. Food and Drug Administration for its first suture-based product, TENSOR™ Suture Button System. Newly launched, next-generation systems include ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws. "The addition of these products to our growing orthopedic trauma portfolio signifies our continued re
AUDUBON, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ADIRA™ XLIF™ Plate System, the Company's first product launch compatible across its expanded lateral interbody portfolio. "This launch represents an important milestone in our integration roadmap," said David Hole, president of Spine at Globus Medical. "Through the system's ability to be paired with our industry-leading Globus and NuVasive interbody spacers, ADIRA™ demonstrates our continued commitment to accelerated procedural innovation in lateral spine surgery." The ADIRA™ XLIF™ Plate System refines lateral
AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net sales were $629.7 million, an increase of 115.9% or 117.3% on a constant currency basisGAAP net income for the quarter was $31.8 millionGAAP diluted earnings per share ("EPS") was $0.23 and non-GAAP diluted EPS was $0.75Non-GAAP adjusted EBITDA was $190.4 million, or 30.2% of net sales "I'm pleased with the quarterly results, demonstrating our team's strong performance as we continue to execute our long-term growth strategy, deliver on NuVasive integration plans, laun
AUDUBON, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it recently received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for ExcelsiusFlex™ with Total Knee Arthroplasty (TKA) application. This new robotic navigation platform joins the already best-in-class Excelsius™ ecosystem, designed to offer surgeons control, resection accuracy, and procedural flexibility in Total Knee Arthroplasty. Additionally, ACTIFY™ 3D Total Knee System, the latest in implant technology that will pair with ExcelsiusFlex™, has also received 510(k) clearance. ExcelsiusFlex™ is engineered to assist the surgeon
AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 6, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast